FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer

The FDA has approved sotorasib (Lumakras, Amgen) with panitumumab (Vectibix, Amgen) for adult patients with KRAS ...

JANUARY 21, 2025

FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer

The FDA granted accelerated approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) with ...

DECEMBER 23, 2024

FDA Grants Accelerated Approval to Krazati With Erbitux for KRAS G12C–Mutated Colorectal Cancer

The FDA has granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics) plus cetuximab (Erbitux, ...

JUNE 24, 2024

New First-Line Option for Highly Mutated CRC?

A new study shows that the dual immunotherapy combination of nivolumab (Opdivo, Bristol Myers Squibb [BMS]) plus ...

FEBRUARY 12, 2024

FDA Approves Fruzaqla in Refractory Metastatic Colorectal Cancer

The FDA approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals) for adult patients with metastatic colorectal ...

NOVEMBER 9, 2023

Panitumumab Extends Survival in Left-Sided Metastatic Colorectal Cancer

In a breakthrough for the treatment of left-sided metastatic colorectal cancer (CRC), panitumumab (Vectibix, Amgen) ...

JUNE 19, 2022

New Dosing Regimen Approved for Erbitux

The FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, ImClone) given intravenously over 120 minutes every ...

APRIL 8, 2021

FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC

The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...

JULY 12, 2018

AACR Report: HER2-Targeted Rx Effective in HER2+ mCRC

In heavily pretreated patients with HER2-positive mCRC, a combination of trastuzumab and lapatinib provided ...

APRIL 6, 2017